Moderna Curbing Investments in Vaccine Trials Due To US Backlash, CEO Says
An anonymous reader shares a report: Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday. "You cannot make a return on investment if you don't have access to the U.S. market," Bancel told Bloomberg TV on the sidelines of the World Economic Forum in Davos. Bancel said regulatory delays and little support from the authorities make the market size "much smaller."

Read more of this story at Slashdot.